Tirzepatide vs Retatrutide
Tirzepatide and retatrutide represent two generations of incretin-based research compounds, both developed by Eli Lilly's research program. Tirzepatide is a dual GLP-1/GIP receptor agonist that entered the market first; retatrutide is the newer triple agonist (GLP-1, GIP, and glucagon receptors) currently in late-stage clinical trials. For researchers studying metabolic pathways, the difference between dual and triple agonism is meaningful.
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor activity | GLP-1 + GIP dual | GLP-1 + GIP + Glucagon triple |
| Development status | FDA-approved | Phase 3 trials (TRIUMPH) |
| Half-life (research data) | ~5 days | ~6 days |
| Phase 2 trial outcomes | ~22.5% (72-week) | ~24-28% (48-68 week) |
| Research availability | Widely available | Newer to research market |
About Tirzepatide
Tirzepatide combines GLP-1 and GIP receptor activity in a single molecule. The GIP component is hypothesized in research to enhance the metabolic effects of GLP-1 activation, potentially explaining the larger effects seen in head-to-head trials versus GLP-1-only compounds. Tirzepatide is the most extensively characterized dual agonist with substantial published data.
About Retatrutide
Retatrutide adds a third pathway — glucagon receptor agonism — to the dual GLP-1/GIP activity of tirzepatide. In published Phase 2 trial data from the TRIUMPH program, retatrutide demonstrated mean weight reductions of approximately 24-28% at 48-68 weeks, compared to roughly 22% with tirzepatide.
Which Should Researchers Choose?
For most metabolic research:
- Established protocols generally use tirzepatide due to its longer track record and larger body of published data.
- Novel triple-agonist research requires retatrutide.
- Cutting-edge research exploring next-generation incretin therapies should consider retatrutide.
Shop these compounds
Frequently Asked Questions
Is retatrutide more effective than tirzepatide?
Published Phase 2 trial data for retatrutide shows numerically larger effects compared to tirzepatide trials. However, head-to-head comparisons have not been published as of this writing.
Is retatrutide FDA approved?
No. Retatrutide is in Phase 3 clinical trials (the TRIUMPH program) and has not yet received FDA approval.
What does triple agonist mean?
Retatrutide binds to and activates three different receptors: GLP-1, GIP, and glucagon. Each pathway contributes differently to metabolic effects.